by
DR » Mon May 16, 2005 5:32 pm
If the tablet is on the market, there should be some specs for the tests you are doing. If you are doing dosage uniformity, the USP typically allows 6% RSD for stage 1, provided all results are between 85-115% of claim. If you are doing a potency assay (also known as composite or stability indicating assay), the USP monograph would provide only a specification with respect to claim (eg: 97-103%) and you would have to refer to your method for internal %RSD limits.
I'm not sure I'd argue the point using Horowitz. You are dealing with a, presumably, validated method and have some history with the sample type you are dealing with.
I would investigate how your samples look compared to previous runs. Are the areas and %RSDs comparable? Is the %RSD for replicate sample preps usually around 5% for Vit. D3? Is this sample any different from the previous samples (longer time on some harsh stability study condition)?
If your %RSDs are typical, I would leave it at that. If they are higher than normal, I would try to determine if this is an expected or an unexpected result. If the standards are unusually high with respect to %RSD, check the equipment. . .